Explain How Seebri and Utibron Stack Up Against Other Inhalers for COPD

Two new glycopyrrolate-containing bronchodilators, Seebri (SEE-bree) and Utibron (YOO-tee-bron) Neohalers, will jostle for a place in the COPD market.

Consider these inhalers as me-too drugs.

Think of the single-agent glycopyrrolate (Seebri) as similar to tiotropium (Spiriva), aclidinium (Tudorza), or umeclidinium (Incruse)...and the indacaterol/glycopyrrolate combo (Utibron) as similar to umeclidinium/vilanterol (Anoro) or tiotropium/olodaterol (Stiolto).

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Not sold to individuals